Clinical trialsCompany release

Zentalis eyes FDA talks on azenosertib accelerated approval after DENALI readout in 1H 2027

🇺🇸 Zentalis Pharmaceuticals, Inc. (ZNTL) · Mon 09 Nov 2026

The US biotech reported Q3 2026 results, said Part 2c enrolment completes in November, and put its cash runway into the first half of 2028.

Zentalis Pharmaceuticals reported third-quarter 2026 results on 9 November, alongside an update on azenosertib, its investigational oral WEE1 inhibitor being developed for Cyclin E1-positive platinum-resistant ovarian cancer.

The company pointed to data presented at ESMO showing median overall survival of 15.9 months in Cyclin E1-positive patients, compared with 7.5 months in Cyclin E1-negative patients. These figures are from an investigational programme and the summary does not give further detail on the analysis.

Zentalis expects to complete enrolment in Part 2c of the DENALI study in November. It then anticipates an integrated topline readout in the first half of 2027. The company plans to discuss the DENALI data with the US Food and Drug Administration in 2027 to assess whether an accelerated approval path is possible. As general context, accelerated approval allows the FDA to grant approval on the basis of a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit, usually with confirmatory trials required.

On finances, Zentalis reported cash of $228.9 million, which it expects to fund operations into the first half of 2028.

What it means for your team

  • Regulatory teams should note that any accelerated approval discussion with the FDA is planned for 2027, after the integrated DENALI topline data, and is not yet agreed.
  • The Cyclin E1 survival split (15.9 versus 7.5 months) underlines the role of biomarker selection, which would be relevant to any companion diagnostic planning.
  • Market-access teams tracking platinum-resistant ovarian cancer should treat azenosertib as an investigational asset, with the key milestones being Part 2c enrolment completion in November and the topline readout in 1H 2027.

Company's press release (SEC filing): Zentalis Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Zentalis Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →